We examined the effect of GRN allele status at rs5848 and TMEM106B variants rs1020004, rs1990622, and rs6966915 on PGRN or IL-6 plasma levels in control subjects (n = 133), AD (n = 82), and FTLD cases, excluding mutations in MAPT, GRN, and C9ORF72 (n = 184), but no significant correlations were seen either for FTLD overall or when stratified according to clinical diagnostic or genetic subgroup (see online Supplementary Tables 1–4). This evidence concerns the gene GRN and Alzheimer disease.